Novartis rises on strong 2nd-qtr financials

18 July 2018
novartis-big

Shares of Swiss pharma giant Novartis (NOVN: VX) were up 2.9% at 80.50 Swiss francs in early trading, after the company released second-quarter 2018 financial results that beat expectations.

Net sales of $13.2 billion in the three months ending June 30 were up 5% per cent on a year earlier in constant currencies, and compared with $12.9 billion expected on average by analysts. Core net income rose 3% to $3.0 billion, also beating expectations. Core operating profit rose 7% to $3.54 billion, compared with average forecast of $3.46 billion in a Reuters poll.

Net income jumped to $7.8 billion, including a $5.7 billion net gain from the sale of Novartis’ stake in a consumer healthcare joint venture to GlaxoSmithKline, compared to $2.0 billion in the prior year,

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical